Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 11:40 PM ET

Biotechnology

Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute. Syndax Pharmaceuticals, Inc. was founded ...

400 Totten Pond Road

Suite 110

Waltham, MA 02451

United States

Founded in 2005

13 Employees

Phone:

781-419-1400

Fax:

781-419-1420

Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer and Director
President and Chief Operating Officer
Age: 44
Co-Founder and Chief Technology Officer
Age: 46
Co-Founder
Age: 58
Co-Founder and Advisor
Compensation as of Fiscal Year 2015.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals Announces Management Changes

Syndax Pharmaceuticals has named Briggs Morrison as CEO and a member of the board, and Michael Metzger as president and COO. Morrison joins Syndax from AstraZeneca, where he was chief medical officer. He replaces Arlene Morris in the CEO role, who left in May to pursue other endeavors, said a company spokeswoman. Metzger joins from Regado Biosciences, where he was president and CEO through the company's strategic merger with Tobira Therapeutics.

Briggs Morrison to Join Syndax Pharmaceuticals as Head of Global Late-Stage Drug Development

Outgoing Chief Medical Officer of AstraZeneca Briggs Morrison will join Syndax Pharmaceuticals. Morrison, who joined the pharmaceutical company in 2012, is also serving the company as head of global late-stage drug development.

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:00 PM

Syndax Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 03:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

Similar Private Companies By Industry

Company Name Region
Stem Cell Innovations, Inc. United States
Koronis Pharma, Inc. United States
Phyllom LLC United States
Kadmon Corporation, LLC United States
Boston Biomedical Research Institute, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 1, 2015
--
Private Placement
January 7, 2015
--
Private Placement
September 18, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Syndax Pharmaceuticals, Inc., please visit www.syndax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.